[go: up one dir, main page]

ATE462803T1 - Kit und verfahren zum nachweis von urothelkarzinom - Google Patents

Kit und verfahren zum nachweis von urothelkarzinom

Info

Publication number
ATE462803T1
ATE462803T1 AT06797321T AT06797321T ATE462803T1 AT E462803 T1 ATE462803 T1 AT E462803T1 AT 06797321 T AT06797321 T AT 06797321T AT 06797321 T AT06797321 T AT 06797321T AT E462803 T1 ATE462803 T1 AT E462803T1
Authority
AT
Austria
Prior art keywords
kit
detecting
protein
urothelic
carcinoma
Prior art date
Application number
AT06797321T
Other languages
English (en)
Inventor
Hideo Akiyama
Yoshinori Tanaka
Satoko Kozono
Hitoshi Nobumasa
Osamu Ogawa
Takeshi Takahashi
Original Assignee
Toray Industries
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Univ Kyoto filed Critical Toray Industries
Application granted granted Critical
Publication of ATE462803T1 publication Critical patent/ATE462803T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT06797321T 2005-09-02 2006-09-01 Kit und verfahren zum nachweis von urothelkarzinom ATE462803T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005255370 2005-09-02
JP2006017379 2006-09-01

Publications (1)

Publication Number Publication Date
ATE462803T1 true ATE462803T1 (de) 2010-04-15

Family

ID=37808979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06797321T ATE462803T1 (de) 2005-09-02 2006-09-01 Kit und verfahren zum nachweis von urothelkarzinom

Country Status (10)

Country Link
US (1) US7910316B2 (de)
EP (1) EP1930445B1 (de)
JP (1) JP5078015B2 (de)
KR (1) KR101393144B1 (de)
CN (1) CN101297046B (de)
AT (1) ATE462803T1 (de)
CA (1) CA2621060A1 (de)
DE (1) DE602006013333D1 (de)
ES (1) ES2343276T3 (de)
WO (1) WO2007026895A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499864B2 (en) 2003-11-03 2016-11-22 Aab Patent Holding Aps Expression of FABP4 and other genes associated with bladder cancer progression
EP2166358A1 (de) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differentialdiagnostisches Biomarker von einen Schlaganfall imitierenden Bedingungen und Verfahren zur Verwendung dieser
CN102245767B (zh) * 2008-10-31 2013-09-18 东丽株式会社 人cxcl1蛋白质的免疫学测定方法
US20110229915A1 (en) * 2008-11-22 2011-09-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2012002208A (es) * 2009-08-25 2012-06-12 Cytotech Labs Llc Metodos para el tratamiento de un sarcoma empleando un cambiador epimetabolico (coenzima q10).
WO2011109810A2 (en) 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
NZ589251A (en) 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
ES2601460T3 (es) 2011-12-30 2017-02-15 Abbott Molecular Inc. Materiales y métodos para el diagnóstico del cáncer de vejiga y el control de la recurrencia del mismo
JP6281873B2 (ja) 2012-10-17 2018-02-21 公立大学法人奈良県立医科大学 新規癌マーカーおよびその利用
CN105505941A (zh) * 2016-01-21 2016-04-20 中国人民解放军第四军医大学 Cxcl1的适配体在制备检测上尿路上皮癌试剂中的应用
WO2020071489A1 (ja) * 2018-10-04 2020-04-09 国立大学法人大阪大学 尿路上皮がんを検査する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309895A (ja) 1994-05-20 1995-11-28 Idemitsu Kosan Co Ltd 新規タンパク質、その検出方法及び診断薬
JPH1054830A (ja) 1996-08-12 1998-02-24 Omomo Souuemon テストストリップの製造システム
JP2000131321A (ja) 1998-10-28 2000-05-12 Igaku Seibutsugaku Kenkyusho:Kk 膀胱癌患者の予後診断薬
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
JP2002238599A (ja) 2001-02-21 2002-08-27 Yoshihiko Funae 膀胱癌の診断方法および診断キット
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
JP4109032B2 (ja) 2002-07-29 2008-06-25 株式会社福山臨床検査センター 膀胱癌の検査判定方法
JP4207187B2 (ja) 2002-09-30 2009-01-14 財團法人奇美醫院 膀胱癌に対する分子マーカーとしてのｈｕｒｐ遺伝子
US20060188889A1 (en) 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
JP2004337120A (ja) 2003-05-19 2004-12-02 Chang Gung Univ 膀胱癌再発検査方法
AU2004245998A1 (en) * 2003-06-04 2004-12-16 The Government of the United States as represented by The Secretary of the Department of Health and Human Services, Centres for Disease Control and Prevention PNI microarray and uses
JP2005255370A (ja) 2004-03-15 2005-09-22 Mitsubishi Electric Corp エレベーターの制御装置

Also Published As

Publication number Publication date
JPWO2007026895A1 (ja) 2009-03-12
KR101393144B1 (ko) 2014-05-08
US20100009347A1 (en) 2010-01-14
EP1930445A1 (de) 2008-06-11
EP1930445B1 (de) 2010-03-31
CN101297046B (zh) 2013-01-02
US7910316B2 (en) 2011-03-22
CA2621060A1 (en) 2007-03-08
EP1930445A4 (de) 2008-12-10
CN101297046A (zh) 2008-10-29
WO2007026895A1 (ja) 2007-03-08
ES2343276T3 (es) 2010-07-27
JP5078015B2 (ja) 2012-11-21
KR20080046693A (ko) 2008-05-27
DE602006013333D1 (de) 2010-05-12

Similar Documents

Publication Publication Date Title
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
BRPI0610092B8 (pt) métodos para a detecção de um analito e de um ácido nucleico em uma amostra, e de sintetização de uma molécula de ácido nucleico ou de análogo de ácido nucleico, kit reagente, uso do mesmo, molécula de ácido nucleico ou de análogo de ácido nucleico e produto associado
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
ATE549625T1 (de) Verfahren und zusammensetzungen zum nachweis einer zervixerkrankung
ATE520026T1 (de) Sequenzielle analyse biologischer proben
WO2009076485A3 (en) Sequencing of nucleic acids
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
MX337666B (es) Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
EP2177614A3 (de) Zusammensetzung und Verfahren zur Diagnose von Speiseröhrenkrebs sowie der Metastasierung von Speiseröhrenkrebs
ATE520979T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
HK1088947A1 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE537191T1 (de) Protein, verfahren zur proteinimmobilisierung, struktur, biosensor, nukleinsäure, vektor und kit für den nachweis einer zielsubstanz
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
DE602004005859D1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
ATE534907T1 (de) Verfahren für den nachweis von l523s-expression in biologischen proben
ATE393393T1 (de) Verwendung des proteins spee als marker für brustkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties